Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It's product portfolio includes DuraGraft, a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure; MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that provides a therapeutics opportunity for wound healing, thrombosis, and pet health. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures. Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. The company was incorporated in 2007 and is based in Jupiter, Florida.